Ketone bodies produced by sodium-glucose cotransporter 2 (SGLT2) inhibitors can be advantageous, providing an efficient and stable energy source for the brain and muscles. However, in patients with diabetes, ketogenesis induced by SGLT2 inhibitors may be harmful, potentially resulting in severe diabetic ketoacidosis (DKA). During fasting, ketone body production serves as an alternative and efficient energy source for the brain by utilizing stored fat, promoting mental clarity, and reducing dependence on glucose. The concurrent use of SGLT2 inhibitors during perioperative fasting may further elevate the risk of euglycemic DKA. We describe a case of DKA that occurred during perioperative fasting in a patient receiving empagliflozin, an SGLT2 inhibitor. This case underscores the importance of recognizing the potential risk of DKA in patients with diabetes using SGLT2 inhibitors during perioperative fasting.
Citations
Citations to this article as recorded by
Hidden risk of euglycemic diabetic ketoacidosis with sodium-glucose cotransporter 2 (SGLT2) inhibitors in emergency general surgery in the United States: a case report Laura Roberson, June Yao, Christina So, Brian Tuai Journal of Acute Care Surgery.2026; 16(1): 70. CrossRef
The simultaneous development of diabetic ketoacidosis (DKA) and thyroid storm (TS) is a rare but potentially lifethreatening condition that requires immediate and targeted treatment. However, their combined diagnosis poses a serious challenge because of the similarities between their clinical manifestations. To date, only a few dozen cases have been described; most of which have been linked to the progression of thyrotoxicosis or uncontrolled hyperglycemia as contributing factors. We present the case of a 37-year-old woman with type 1 diabetes mellitus and Graves’ disease who presented with both TS and DKA. She was initially admitted to the emergency department as a suspected case of stroke. Severe hypoglycemia significantly lowered her alertness to TS and probably provoked a sharp hyperthyroid decompensation, thereby leading to subsequent DKA development.
Background The use of euglycemic diabetic ketoacidosis (EDKA) related to sodium-glucose cotransporter 2 inhibitors (SGLT2i) use in people with diabetes has been increasingly reported. The causes are multifactorial, and dietary changes in SGLT2i users were observed to trigger EDKA. A ketogenic diet or very low-carbohydrate diet (VLCD) enhances body ketosis by breaking down fats into energy sources, causing EDKA. This study aimed to understand the patient specific risk factors and clinical characteristics of this cohort.
Methods Several databases were carefully analyzed to understand the patients’ symptoms, clinical profile, laboratory results, and safety of dietary changes in SGLT2i’s. Thirteen case reports identifying 14 patients on a ketogenic diet and SGLT2i’s diagnosed with EDKA were reviewed.
Results Of the 14 patients, 12 (85%) presented with type-2 diabetes mellitus (DM) and 2 (15%) presented with type-1 DM. The duration of treatment with SGLT2i before the onset of EDKA varies from 1 to 365 days. The duration of consuming a ketogenic diet or VLCD before EDKA onset varies from 1 to 90 days, with over 90% of patients hospitalized <4 weeks after starting the diet. At presentation, average blood glucose was 167.50±41.80 mg/dL, pH 7.10±0.10, HCO3 8.1±3.0 mmol/L, potassium 4.2±1.1 mEq/L, anion-gap 23.6±3.5 mmol/L, and the average hemoglobin A1c was 10%±2.4%. The length of hospital stay ranged from 1 to 15 days. None of the patients were reinitiated on SGLT2i’s, and 50% (2/4) of the patients reported were on the ketogenic diet or VLCD upon patient questioning.
Conclusion Despite the popularity of the ketogenic diet and VLCD for weight loss, their use in diabetics taking SGLT2i’s is associated with EDKA. Physicians should educate patients with diabetes taking SGLT2i’s about the risk of EDKA. In addition, patients should be encouraged to include their physicians in any decision related to significant changes in diet or exercise routines. Further research is needed to address if SGLT2i’s should be permanently discontinued in patients with diabetes on SGLT2i and whether the ketogenic diet developed EDKA.
Citations
Citations to this article as recorded by
Euglycemic Diabetic Ketoacidosis: Clinical Suspicion and Diagnosis Ravi Shukla, Puja Shrestha, Binod Khanal, Bipal Regmi Clinical Medicine Insights: Endocrinology and Diabetes.2026;[Epub] CrossRef
A Single Arm Pilot Observational Study to Evaluate the Safety and Feasibility of a Pre‐Operative Very Low Calorie Diet in Severely Obese Patients With Endometrial Cancer Chloe Ayres, Hanna Burbidge, Jayna Garratt, Ganendra Raj Mohan, Yee Leung, Stephanie Jeffares, Sanela Bilic, Paul A. Cohen Cancer Reports.2025;[Epub] CrossRef
Lifestyle prescriptions for diabetes management in primary care: a narrative review Hye Jun Lee, Jung-Ha Kim Ewha Medical Journal.2025; 48(4): e55. CrossRef
From Sweet to Sour: SGLT-2-Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Andrijana Koceva, Nika Aleksandra Kravos Tramšek Journal of Personalized Medicine.2024; 14(7): 665. CrossRef
We report the first case of hypoglycemia and lactic acidosis caused by the therapeutic doses of venlafaxine. A 19-year-old female patient had presyncope and she was taking venlafaxine 75 mg once a day because of major depression for a week and she had no history of any other drug use or disease. The blood gas analysis revealed hypoglycemia and lactic acidosis. Patient was treated with dextrose infusion and oral diet. Although hypoglycemia and lactic acidosis have been reported in overdose of venlafaxine in the literature, these effects were observed in therapeutic doses.
Citations
Citations to this article as recorded by
The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database Santosh Chokkakula, Hualiang Yang, Abeer A. Al-Masri, Yiquan Zhang, Bommireddy Naveen, Bing Yang Frontiers in Pharmacology.2026;[Epub] CrossRef
Venlafaxine-induced serotonin syndrome causing bilateral cerebral strokes: a case report Nils Mein, Khadija Mammadli, Felix Luessi, Timo Uphaus Frontiers in Stroke.2025;[Epub] CrossRef
Seizure, Rhabdomyolysis, and Hypoglycemia in a Patient With Venlafaxine Poisoning Akif Yarkaç, Çağri Safa Buyurgan, Ataman Köse, Seyran Bozkurt Babuş Journal of Clinical Psychopharmacology.2023; 43(6): 546. CrossRef
Dose-related hypoglycemia in venlafaxine poisoning: a retrospective cohort study Elias Bekka, Florian Eyer Clinical Toxicology.2022; 60(12): 1336. CrossRef
First
Prev
